Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.400 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Avrobio Inc

< Previous 1 2 3 4 Next >
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML
Palantir stock is on the rise Thursday as PLTR investors react to a new $19 million contract for the big data and AI company. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday. 
Via InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning! 
Via InvestorPlace
AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024
AVRO stock results show that Avrobio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Avrobio Shares Are Rising Wednesday
AVROBIO Inc (NASDAQ: AVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives. 
Via Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
  
Via Benzinga
Recap: Avrobio Q1 Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy
Via Benzinga
Recap: Avrobio Q2 Earnings
  Avrobio (NASDAQ:AVRO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga
Dow Tumbles 100 Points; Micron Technology Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping over 100 points on Monday. The Dow traded down 0.36% to 33,306.30 while the NASDAQ rose 0.39% to 12,707.21. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded down 0.20% to 33,359.71 while the NASDAQ rose 0.47% to 12,717.37. The S&P... 
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS). 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Avrobio Inc (NASDAQ: AVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months
Avrobio Inc (NASDAQ: AVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023'
New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3... 
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.